Cost-effectiveness and Budgetary Consequence Analysis of Durvalumab Consolidation Therapy vs No Consolidation Therapy After Chemoradiotherapy in Stage III Non–Small Cell Lung Cancer in the Context of the US Health Care System | Zendy

Steven D. Criss | Zendy; Meghan J. Mooradian | Zendy; Deirdre F. Sheehan | Zendy; Leyre Zubiri | Zendy; Melissa Lumish | Zendy; Justin F. Gainor | Zendy; Kerry L. Reynolds | Zendy; Chung Yin Kong | Zendy

Open Access

Cost-effectiveness and Budgetary Consequence Analysis of Durvalumab Consolidation Therapy vs No Consolidation Therapy After Chemoradiotherapy in Stage III Non–Small Cell Lung Cancer in the Context of the US Health Care System

Author(s) -

Steven D. Criss,

Meghan J. Mooradian,

Deirdre F. Sheehan,

Leyre Zubiri,

Melissa Lumish,

Justin F. Gainor,

Kerry L. Reynolds,

Chung Yin Kong

Publication year - 2018

Publication title -

jama oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 8.846

H-Index - 99

eISSN - 2374-2445

pISSN - 2374-2437

DOI - 10.1001/jamaoncol.2018.5449

Subject(s) - medicine , durvalumab , chemoradiotherapy , lung cancer , context (archaeology) , oncology , cancer , immunotherapy , pembrolizumab , paleontology , biology

In early 2018, durvalumab became the first immunotherapy to be approved for adjuvant treatment of patients with unresectable stage III non-small cell lung cancer (NSCLC) whose cancer has not progressed after definitive chemoradiotherapy. However, the cost-effectiveness and potential economic implications of using this high-priced therapy in this indication are unknown to date.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research